For­mer As­traZeneca ex­ec com­mit­ted in­sid­er trad­ing on land­mark 2019 En­her­tu deal, SEC al­leges

A for­mer As­traZeneca em­ploy­ee al­leged­ly en­gaged in in­sid­er trad­ing while at the Big Phar­ma, ac­cord­ing to an SEC com­plaint sub­mit­ted last week.

In March 2019, Hugues Pierre Jou­blin learned the com­pa­ny was in con­fi­den­tial ne­go­ti­a­tions with Dai­ichi Sankyo for a glob­al de­vel­op­ment and com­mer­cial­iza­tion pact for Dai­ichi’s an­ti­body-drug con­ju­gate that would come to be known as En­her­tu. He was glob­al head of cor­po­rate af­fairs for AZN’s on­col­o­gy di­vi­sion at the time, when he learned of the deal ne­go­ti­a­tions on March 6.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER